Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.73 |
| ▸ | FYN | P06241 | 5/20 | 0.60 |
| ▸ | ABL1 | P00519 | 5/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | LYN | P07948 | 4/20 | 0.60 |
| ▸ | BLK | P51451 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.60 |
| ▸ | YES1 | P07947 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | FGR | P09769 | 2/20 | 0.60 |
| ▸ | HCK | P08631 | 2/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.60 |
| ▸ | PRKACA | P17612 | 2/20 | 0.60 |
| ▸ | FRK | P42685 | 2/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784286 | 0.87 | SRC (0.61) | SRCFYNABL1EGFRLYN | |
| SCHEMBL13019674 | 0.84 | SRC (1.00) | SRCFYNABL1EGFRLYN | |
| SCHEMBL13019672 | 0.78 | SRC (0.69) | SRCFYNABL1EGFRLYN | |
| SCHEMBL13019685 | 0.77 | PIK3CD (0.73) | SRCFYNABL1EGFRLYN | |
| SCHEMBL15086960 | 0.76 | SRC (0.70) | SRCFYNABL1EGFRLYN | |
| SCHEMBL13020038 | 0.76 | SRC (0.64) | SRCFYNABL1EGFRLYN | |
| SCHEMBL375322 | 0.75 | SRC (1.00) | SRCFYNABL1EGFRLYN | |
| SCHEMBL12435990 | 0.75 | SRC (0.76) | SRCABL1EGFRKDRHCK | |
| SCHEMBL29355398 | 0.75 | SRC (1.00) | SRCFYNABL1EGFRLYN | |
| SCHEMBL13019687 | 0.75 | CYP1A2 (0.75) | SRCFYNABL1EGFRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885FYN 950/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.